Erin Michos, MD
@erinmichos.bsky.social
Cardiologist 🫀 & Researcher (women's health & CVD prevention). Professor at Johns Hopkins School of Medicine. Mother of a teenager. Loves travel ✈️, Barre classes, running 🏃♀️, & coffee ☕️ . She/hers
Congratulations to our @hopkinsheart.bsky.social research fellow Dr @zaibhussain10.bsky.social on being a #QCOR Early Career Finalist at #AHA2025 ! 👏👏Check out her presentation Friday with simultaneous publication in Circ Outcomes on motivational themes for CV trial enrollment.
November 6, 2025 at 6:01 PM
Congratulations to our @hopkinsheart.bsky.social research fellow Dr @zaibhussain10.bsky.social on being a #QCOR Early Career Finalist at #AHA2025 ! 👏👏Check out her presentation Friday with simultaneous publication in Circ Outcomes on motivational themes for CV trial enrollment.
FINE-ONE was just presented at @asnkidney.bsky.social at #KidneyWk. #Finerenone significantly reduced #UACR by 25% at 6 months in patients with #T1D & #CKD - an understudied population with high unmet need.
November 6, 2025 at 3:08 PM
FINE-ONE was just presented at @asnkidney.bsky.social at #KidneyWk. #Finerenone significantly reduced #UACR by 25% at 6 months in patients with #T1D & #CKD - an understudied population with high unmet need.
Join me in Nashville Sept 5-7 for the American Society of Echocardiography @ase360.bsky.social Scientific Sessions and 50th year Anniversary! Join us for late breaking innovations & updates in cardiovascular ultrasound. #echofirst #ASE2025 #EchoSky
May 13, 2025 at 10:26 PM
Join me in Nashville Sept 5-7 for the American Society of Echocardiography @ase360.bsky.social Scientific Sessions and 50th year Anniversary! Join us for late breaking innovations & updates in cardiovascular ultrasound. #echofirst #ASE2025 #EchoSky
Pleased to share our results from the TANDEM Trial published in @thelancet.bsky.social today and presented at EAS: Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction: a phase 3, randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan...
May 8, 2025 at 2:04 AM
Pleased to share our results from the TANDEM Trial published in @thelancet.bsky.social today and presented at EAS: Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction: a phase 3, randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan...
Please to share our state of the art review on "Sex Hormones and Heart Failure Risk" in @jaccjournals.bsky.social #JACCAdv led by Dr. Imo Ebong. Find it here at:
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...
April 18, 2025 at 4:08 PM
Please to share our state of the art review on "Sex Hormones and Heart Failure Risk" in @jaccjournals.bsky.social #JACCAdv led by Dr. Imo Ebong. Find it here at:
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...
I'm excited to be a part of "Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing CV Risk on 5/30/2025" at @nationallipid.bsky.social Scientific Sessions. Activity agenda & registration can be found here: events.vindicocme.com/15kYU86/5a2B...
@vindicomeded.bsky.social #lipids #CME
@vindicomeded.bsky.social #lipids #CME
April 18, 2025 at 4:04 PM
I'm excited to be a part of "Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing CV Risk on 5/30/2025" at @nationallipid.bsky.social Scientific Sessions. Activity agenda & registration can be found here: events.vindicocme.com/15kYU86/5a2B...
@vindicomeded.bsky.social #lipids #CME
@vindicomeded.bsky.social #lipids #CME
Exciting new development in lipid field! The early Phase 2 #PURSUIT trial showed a novel oral #PCSK9i (that can be taken with food) lowered LDL-C by 51% at 12 weeks. 84% achieved LDL-C of <70 mg/dL. #ACC25 @accintouch.bsky.social
March 31, 2025 at 4:43 PM
Exciting new development in lipid field! The early Phase 2 #PURSUIT trial showed a novel oral #PCSK9i (that can be taken with food) lowered LDL-C by 51% at 12 weeks. 84% achieved LDL-C of <70 mg/dL. #ACC25 @accintouch.bsky.social
Happy to catch up with the Hopkins Ciccarone Center Prevention Fellows at the #ACC25 Women in Cardiology networking event. Packed room of women, ready to take #ACTION against #CVD. @accintouch.bsky.social
@hopkinsheart.bsky.social
@ciccaronecenter.bsky.social
@hopkinsheart.bsky.social
@ciccaronecenter.bsky.social
March 31, 2025 at 2:25 AM
Happy to catch up with the Hopkins Ciccarone Center Prevention Fellows at the #ACC25 Women in Cardiology networking event. Packed room of women, ready to take #ACTION against #CVD. @accintouch.bsky.social
@hopkinsheart.bsky.social
@ciccaronecenter.bsky.social
@hopkinsheart.bsky.social
@ciccaronecenter.bsky.social
#ExpectMoreForLDL. Working together towards combating #ASCVD, the leading cause of morbidity & mortality. Exciting new options for LDL-C lowering. #ACC25
@newamsterdampharma.bsky.social
@newamsterdampharma.bsky.social
March 31, 2025 at 1:56 AM
#ExpectMoreForLDL. Working together towards combating #ASCVD, the leading cause of morbidity & mortality. Exciting new options for LDL-C lowering. #ACC25
@newamsterdampharma.bsky.social
@newamsterdampharma.bsky.social
#SOUL trial presented at #ACC25. Oral #semaglutide reduced 3-pt major adverse cardiovascular events by 14% in patients with T2D, even with high background SGLTi use. In exploratory analysis, oral sema also reduced major limb events. #CardioSky @accintouch.bsky.social
March 29, 2025 at 6:46 PM
#SOUL trial presented at #ACC25. Oral #semaglutide reduced 3-pt major adverse cardiovascular events by 14% in patients with T2D, even with high background SGLTi use. In exploratory analysis, oral sema also reduced major limb events. #CardioSky @accintouch.bsky.social
Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky
March 29, 2025 at 3:13 PM
Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky
Thank you @hopkinsheart.bsky.social ! I am very excited about our outstanding incoming cardiology 🫀 fellowship class and look forward to working with them! @tleucker.bsky.social
December 17, 2024 at 12:56 PM
Thank you @hopkinsheart.bsky.social ! I am very excited about our outstanding incoming cardiology 🫀 fellowship class and look forward to working with them! @tleucker.bsky.social
At the CVI Philadelphia Conference, Dr @mmukherjeemd.bsky.social educated us about CV risk assessment in individuals with systemic inflammation and autoimmune diseases. #CardioSky
December 7, 2024 at 7:41 PM
At the CVI Philadelphia Conference, Dr @mmukherjeemd.bsky.social educated us about CV risk assessment in individuals with systemic inflammation and autoimmune diseases. #CardioSky
Excited to present today at CVI Cardiovascular Institute's 11th annual imaging conference with a focus on women's health, chaired by Dr Renee Bullock-Palmer. I will be speaking about CV risks associated with adverse pregnancy outcomes & opportunities for prevention. #CardioSky #CardioObstetrics
December 7, 2024 at 1:13 PM
Excited to present today at CVI Cardiovascular Institute's 11th annual imaging conference with a focus on women's health, chaired by Dr Renee Bullock-Palmer. I will be speaking about CV risks associated with adverse pregnancy outcomes & opportunities for prevention. #CardioSky #CardioObstetrics
Excited to welcome our in-coming CV fellows to
@hopkinsheart.bsky.social .
Looking forward to working with you! #CardioSky 🫀❤️
@hopkinsheart.bsky.social .
Looking forward to working with you! #CardioSky 🫀❤️
December 4, 2024 at 9:36 PM
Excited to welcome our in-coming CV fellows to
@hopkinsheart.bsky.social .
Looking forward to working with you! #CardioSky 🫀❤️
@hopkinsheart.bsky.social .
Looking forward to working with you! #CardioSky 🫀❤️
Sharing the @americanheart.bsky.social scientific statement about asssessing & addressing CV health in individuals who are transgender and gender diverse. Transgender care is health care, and I support optimizing the lives & hearts of all persons. 🏳️🌈
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
December 4, 2024 at 2:16 PM
Sharing the @americanheart.bsky.social scientific statement about asssessing & addressing CV health in individuals who are transgender and gender diverse. Transgender care is health care, and I support optimizing the lives & hearts of all persons. 🏳️🌈
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
"Live life with egrets, not with regrets".
November 30, 2024 at 10:10 PM
"Live life with egrets, not with regrets".
#Birds of the #OuterBanks. Posting some photos I took over Thanksgiving break.
November 30, 2024 at 10:01 PM
#Birds of the #OuterBanks. Posting some photos I took over Thanksgiving break.
Yay! Welcome, Johns Hopkins Cardiology to where the skies are blue. 🦋 🫀
@hopkinsheart.bsky.social
#CardioSky
@hopkinsheart.bsky.social
#CardioSky
November 22, 2024 at 9:11 PM
Yay! Welcome, Johns Hopkins Cardiology to where the skies are blue. 🦋 🫀
@hopkinsheart.bsky.social
#CardioSky
@hopkinsheart.bsky.social
#CardioSky
Now out in #JAHA @ahajournals.bsky.social , our study led by Seye Ogunmoroti & @olaosi.bsky.social which found "Work‐Related Stress Is Associated With Unfavorable Cardiovascular Health: The Multi‐Ethnic Study of Atherosclerosis", #CardioSky
www.ahajournals.org/doi/full/10....
November 21, 2024 at 10:59 PM
Now out in #JAHA @ahajournals.bsky.social , our study led by Seye Ogunmoroti & @olaosi.bsky.social which found "Work‐Related Stress Is Associated With Unfavorable Cardiovascular Health: The Multi‐Ethnic Study of Atherosclerosis", #CardioSky
www.ahajournals.org/doi/full/10....
Was an honor to moderate this lipid late breaking clinical trial session. Thanks for all the audience that stayed to the very end of #AHA24 to hear this great science. #CardioSky @ahascience.bsky.social
November 18, 2024 at 11:36 PM
Was an honor to moderate this lipid late breaking clinical trial session. Thanks for all the audience that stayed to the very end of #AHA24 to hear this great science. #CardioSky @ahascience.bsky.social
November 18, 2024 at 9:17 PM
Our #AHA #SFRN fellow Dr Zaib Hussain is presenting on the impact of internet use on knowledge about clinical trial enrollment in diverse populations. #AHA24 #CardioSky @americanheart.bsky.social @tbplante.bsky.social
November 18, 2024 at 6:01 PM
Our #AHA #SFRN fellow Dr Zaib Hussain is presenting on the impact of internet use on knowledge about clinical trial enrollment in diverse populations. #AHA24 #CardioSky @americanheart.bsky.social @tbplante.bsky.social
Dr Christie Ballantyne presents the open label extension of #plozasiran from MUIR and SHASTA-2 trials showing persistent reduction in TGs by ~70% with continued safety out to 24 months. #AHA24 #CardioSky #lipids
November 18, 2024 at 5:02 PM
Dr Christie Ballantyne presents the open label extension of #plozasiran from MUIR and SHASTA-2 trials showing persistent reduction in TGs by ~70% with continued safety out to 24 months. #AHA24 #CardioSky #lipids